These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 30619750)

  • 1. The Potential Clinical Utility of Circulating Tumor DNA in Esophageal Adenocarcinoma: From Early Detection to Therapy.
    Kosovec JE; Zaidi AH; Pounardjian TS; Jobe BA
    Front Oncol; 2018; 8():610. PubMed ID: 30619750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of Circulating Tumor DNA in Plasma: A Potential Biomarker for Esophageal Adenocarcinoma.
    Egyud M; Tejani M; Pennathur A; Luketich J; Sridhar P; Yamada E; Ståhlberg A; Filges S; Krzyzanowski P; Jackson J; Kalatskaya I; Jiao W; Nielsen G; Zhou Z; Litle V; Stein L; Godfrey T
    Ann Thorac Surg; 2019 Aug; 108(2):343-349. PubMed ID: 31059681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.
    Pereira E; Camacho-Vanegas O; Anand S; Sebra R; Catalina Camacho S; Garnar-Wortzel L; Nair N; Moshier E; Wooten M; Uzilov A; Chen R; Prasad-Hayes M; Zakashansky K; Beddoe AM; Schadt E; Dottino P; Martignetti JA
    PLoS One; 2015; 10(12):e0145754. PubMed ID: 26717006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumor DNA detection: A potential tool for colorectal cancer management.
    Li H; Jing C; Wu J; Ni J; Sha H; Xu X; Du Y; Lou R; Dong S; Feng J
    Oncol Lett; 2019 Feb; 17(2):1409-1416. PubMed ID: 30675194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
    Cheng F; Su L; Qian C
    Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
    Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
    PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA).
    Lim M; Kim CJ; Sunkara V; Kim MH; Cho YK
    Micromachines (Basel); 2018 Feb; 9(3):. PubMed ID: 30424034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating Tumor DNA for Early Cancer Detection.
    Fiala C; Kulasingam V; Diamandis EP
    J Appl Lab Med; 2018 Sep; 3(2):300-313. PubMed ID: 33636948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.
    Pécuchet N; Zonta E; Didelot A; Combe P; Thibault C; Gibault L; Lours C; Rozenholc Y; Taly V; Laurent-Puig P; Blons H; Fabre E
    PLoS Med; 2016 Dec; 13(12):e1002199. PubMed ID: 28027313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma.
    Loft M; Lee B; Tie J; Gibbs P
    J Pers Med; 2019 Jul; 9(3):. PubMed ID: 31323810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Use of Circulating Tumor DNA to Monitor and Predict Response to Treatment in Colorectal Cancer.
    Reece M; Saluja H; Hollington P; Karapetis CS; Vatandoust S; Young GP; Symonds EL
    Front Genet; 2019; 10():1118. PubMed ID: 31824558
    [No Abstract]   [Full Text] [Related]  

  • 12. Toward liquid biopsies in cancer treatment: application of circulating tumor DNA.
    Barlebo Ahlborn L; Østrup O
    APMIS; 2019 May; 127(5):329-336. PubMed ID: 30784124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility and applicability of circulating tumor DNA testing in esophageal cancer: a systematic review and meta-analysis.
    Chidambaram S; Markar SR
    Dis Esophagus; 2022 Feb; 35(2):. PubMed ID: 34286823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management.
    Elazezy M; Joosse SA
    Comput Struct Biotechnol J; 2018; 16():370-378. PubMed ID: 30364656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic Treatment Stratification Using ctDNA.
    Vidal J; Taus A; Montagut C
    Recent Results Cancer Res; 2020; 215():263-273. PubMed ID: 31605234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
    Hicks JK; Saller J; Wang E; Boyle T; Gray JE
    Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promising clinical application of ctDNA in evaluating immunotherapy efficacy.
    Li L; Zhang J; Jiang X; Li Q
    Am J Cancer Res; 2018; 8(10):1947-1956. PubMed ID: 30416847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review.
    Chen X; Wang L; Lou J
    Med Sci Monit; 2020 Mar; 26():e921040. PubMed ID: 32200389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.
    Alix-Panabières C; Pantel K
    Cancer Discov; 2016 May; 6(5):479-91. PubMed ID: 26969689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
    Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R
    J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.